Multinational pharmaceutical giant stakes new move to restructure China business

on May 19, Sanofi, a multinational pharmaceutical company, announced that its China regional organizational framework will be in line with the global framework, implement ingress with the global business unit, restructure its China operations according to the three core global business units of specialty drugs, generic drugs and vaccines, and appoint the corresponding headsamong the, general manager and president of China, General Manager of The Global Business Unit of General Medicine, is currently president of Sanofi ChinaThe business team for this division includes cardiovascular and mature products, primary care, diabetes, business and retailGeneral Manager of China, Global Division of Special Medicines, and is currently the General Manager of Special Pharmaceuticals Division, Wang BaikangIts products include Dabitowe, rare and rare blood diseases, new product planning and business innovation teamsThe China team of The Vaccine Global Division remained largely unchangedit is understood that before, Sanofi China's business is mainly divided into drugs and vaccinesAfter this adjustment, Sanofi will formally form an organizational structure of three core business units worldwideAmong them, special drugs cover immune, rare diseases, blood, neurotumor and other fields; The consumer health business operates independentlyin fact, the adjustment was revealed in December 19On December 9, 2019, Sanofi CEO Paul Hudson announced a new strategic framework, "All-in-One," which he said would lead Sanofi into the next cycle and set up three global divisions of generics, specials and vaccines, as well as an independent consumer health business unit, it's not the first time Sanofi has made a big adjustment to ChinaIn 2019, Sanofi China underwent at least three major changes, including the transfer of Sanofi Brazil President He En-ho to President of Sanofi's China and Emerging Markets Global Division, the split or reorganization of Sanofi China's Central Nervous System Division, Internal Medicine Division and Diabetes Division, and Sanofi's Diabetes Division split into two teams of oral drugs and needlesthe author noted that behind it, Sanofi China's performance in recent years has slowedIn terms of Sanofi's growth rate, it fell from 15.1% in 2017 to 8.8% in 2019 In the first quarter of this year, Sanofi's revenue in China even showed negative growth, down 14.4% year-on-year Sanofi's first-quarter results showed that China's revenue decline was mainly due to the impact of band purchases, resulting in a significant increase in sales of large varieties such as Bolewi (clopidogrel), Ambovi/Ambono (Ebesatan/Ebesatan hydrochlorpyrifos), but revenue declined, with revenue falling 13.2% in the first quarter Among them, Boleville sales revenue fell 53.5%, Ambovi, Ambono sales revenue fell by more than 30% year-on-year to adjust the framework for the Sanofi, which the industry believes is either designed to ease performance pressure in China From a broad background, in order to adapt to the policy and market changes in China, enterprises to take more action to ease the performance pressure, in addition to Sanofi, there are many multinational pharmaceutical companies in China and even the global business to make adjustments, such as Pfizer, Roche, AbbVie and so on May, Pfizer's anti-infection team structure was restructured to strip Tyco (injectable tetracycline) and Vivan (Volicon tablets) from its original product line, bringing the team closer to the sub-sector The sichemy (azithromycin) affected by the volume purchase is off the mark in the band purchase, or will be diverted to the retail or grass-roots market Roche also recently announced plans to invest $180 million in its Roche Diagnostics Asia-Pacific production base and research and development center in Suzhou Industrial Park to further deepen the strategic layout of its diagnostic business in China The business will grow 5 percent in the first quarter of 2020, close to 7 percent for drugs, or will be a focus for Roche' power The acquisition of Aberystwyth for $63 billion, and the new company consolidates AbbVie's global business of brands in the fields of immunity, blood tumors, Suchu, Emin, Venclexta, and ElJian in neuroscience overall, the next market competition between multinational pharmaceutical giants will be fiercer, with strategic adjustments may be more frequent.